CCR3-Binding Polypeptide for Targeted Immuno-Regulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic approaches for modulating chemokine activity or their receptors often lead to adverse effects due to indiscriminate blocking of receptor action, and there is a need for targeted methods to address CCR3-mediated diseases such as asthma and autoimmune conditions.
Innovation Solution
A polypeptide with the amino acid sequence shown in SEQ ID NO: 1, derived from the N-terminal extension domain of asparaginyl-tRNA synthetase, exhibits chemokine activity by binding to CCR3, enabling specific detection, diagnosis, and targeted drug delivery for CCR3-mediated diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional receptor antagonists are used to block CCR3 action, then chemokine-mediated diseases can be treated, but adverse effects occur due to indiscriminate blocking of receptor action
Solution Approach 1:
The patent segments the chemokine molecule into a specific polypeptide fragment (amino acid sequence of SEQ ID NO: 1) that selectively binds to CCR3. This segmentation allows targeted inhibition of pathological chemokine-CCR3 interactions while preserving other receptor-ligand interactions, thereby treating diseases with reduced adverse effects compared to broad-spectrum antagonists
Solution Approach 2:
The patent introduces a polypeptide fragment as an intermediary substance that specifically binds to CCR3 and blocks pathological chemokine activity. This intermediary approach allows selective modulation of disease-causing chemokine-receptor interactions without indiscriminately blocking all CCR3-mediated functions, thus improving therapeutic reliability while reducing harmful side effects
2Reliability
If chemokine activity is modulated to treat diseases, then therapeutic benefit is achieved, but lack of specificity leads to excessive suppression of favorable function
Solution Approach 1:
The patent applies local quality by designing a polypeptide fragment with specific amino acid sequence (SEQ ID NO: 1) that exhibits selective binding affinity for CCR3. This localized specificity ensures that therapeutic action is concentrated on pathological processes involving CCR3, while preserving favorable physiological functions mediated by other chemokine-receptor interactions
3Reliability
If receptor action is blocked indiscriminately, then broad chemokine-mediated pathways are inhibited, but adaptation state develops leading to pathologic entry
Solution Approach 1:
By segmenting the chemokine into a specific polypeptide fragment that selectively targets CCR3, the patent avoids broad-spectrum receptor blockade. This selective approach prevents the development of adaptation states and pathologic entry that occur with indiscriminate antagonism, thereby maintaining long-term therapeutic stability while preserving beneficial physiological functions
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The polypeptide effectively binds to CCR3, facilitating immuno-regulation, detection, diagnosis, and treatment of CCR3-mediated diseases, offering a more specific and effective therapeutic option compared to traditional receptor antagonists.
Implementation Method 1
The polypeptide with the amino acid sequence shown in SEQ ID NO: 1, derived from the N-terminal extension domain of asparaginyl-tRNA synthetase, exhibits chemokine activity by binding to CCR3
Data Source
AI summary
A polypeptide having chemokine activity mediated by binding to C-C chemokine receptor type 3 (CCR3) comprising SEQ ID NO: 1 and uses thereof are described.